Sergi Valero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5554053/publications.pdf

Version: 2024-02-01

147801 214800 3,116 122 31 47 citations h-index g-index papers 130 130 130 4695 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nurse admissions at a specialized mental health programme: A preâ€Covidâ€19 retrospective review (2000–2019). Journal of Advanced Nursing, 2022, 78, 2807-2814.	3.3	1
2	Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. Alzheimer's Research and Therapy, 2022, 14, 43.	6.2	8
3	Help Seeking of Highly Specialized Mental Health Treatment before and during the COVID-19 Pandemic among Health Professionals. International Journal of Environmental Research and Public Health, 2022, 19, 3665.	2.6	4
4	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. International Journal of Molecular Sciences, 2022, 23, 6891.	4.1	13
5	Long runs of homozygosity are associated with Alzheimer's disease. Translational Psychiatry, 2021, 11, 142.	4.8	6
6	Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. Scientific Reports, $2021,11,6448.$	3.3	36
7	The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening. Alzheimer's Research and Therapy, 2021, 13, 95.	6.2	13
8	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
9	From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery. Journal of Alzheimer's Disease, 2021, 81, 1541-1553.	2.6	11
10	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	7.9	30
11	Complementary preâ€screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project. Alzheimer's and Dementia, 2021, , .	0.8	3
12	BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols. Journal of Alzheimer's Disease, 2021, 83, 1233-1249.	2.6	7
13	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project. Journal of Alzheimer's Disease, 2021, 83, 1149-1159.	2.6	4
14	Strengths and Difficulties Questionnaire: Psychometric Properties and Normative Data for Spanish 5-to 17-Year-Olds. Assessment, 2021, 28, 1445-1458.	3.1	27
15	Characteristics of resident physicians accessing a specialised mental health service: a retrospective study. BMJ Open, 2021, 11, e055184.	1.9	2
16	Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 718949.	3.4	9
17	Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort. Scientific Reports, 2020, 10, 17721.	3.3	5
18	Relationship between depressive disorders and personality traits: the value of the alternative five factor model. Current Psychology, 2020, , $1.$	2.8	1

#	Article	IF	CITATIONS
19	Interaction of neuropsychiatric symptoms with APOE $\hat{l}\mu 4$ and conversion to dementia in MCI patients in a Memory Clinic. Scientific Reports, 2020, 10, 20058.	3.3	13
20	Dementia Care in Times of COVID-19: Experience at Fundaci \tilde{A}^3 ACE in Barcelona, Spain. Journal of Alzheimer's Disease, 2020, 76, 33-40.	2.6	38
21	Assessing high risk of suicide amongst physicians and nurses in treatment. Psychiatry Research, 2020, 291, 113237.	3.3	7
22	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 25.	6.2	24
23	Personality Factors and Subjective Cognitive Decline: The FACEHBI Cohort. Behavioural Neurology, 2020, 1-6.	2.1	7
24	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
25	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. Scientific Reports, 2020, 10, 1580.	3.3	22
26	Integral Treatment Programme for Addicted Physicians: Results from The Galatea Care Programme for Sick Physicians. European Addiction Research, 2020, 26, 122-130.	2.4	5
27	Family physicians with mental disorders admitted to a physicians' health programme: what can be learned?. Family Practice, 2020, 37, 655-660.	1.9	2
28	Association between retinal thickness and \hat{l}^2 -amyloid brain accumulation in individuals with subjective cognitive decline: Fundaci \tilde{A}^3 ACE Healthy Brain Initiative. Alzheimer's Research and Therapy, 2020, 12, 37.	6.2	24
29	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.8	111
30	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Scientific Reports, 2019, 9, 8698.	3.3	32
31	The MOPEAD project: Advancing patient engagement for the detection of "hidden―undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
32	The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE Îμ4 Non-carriers. Frontiers in Aging Neuroscience, 2019, 11, 327.	3.4	27
33	The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. Scientific Reports, 2018, 8, 3828.	3.3	28
34	The Role of Verb Fluency in the Detection of Early Cognitive Impairment inÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 611-619.	2.6	39
35	Exploring <i>APOE</i> genotype effects on Alzheimer's disease risk and amyloid \hat{l}^2 burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. Alzheimer's and Dementia, 2018, 14, 634-643.	0.8	33
36	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	3.4	12

#	Article	IF	Citations
37	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. Scientific Reports, 2018, 8, 16345.	3.3	52
38	Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the FundaciÃ ³ ACE Healthy Brain Initiative (FACEHBI). Alzheimer's Research and Therapy, 2018, 10, 119.	6.2	46
39	Cigarette dependence and depressive symptoms as predictors of smoking status at five-year follow-up after a workplace smoking cessation program. Addictive Behaviors, 2017, 73, 9-15.	3.0	7
40	Impact of Recruitment Methods in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2017, 57, 625-632.	2.6	26
41	Psychopathology and traffic violations in subjects who have lost their driving license. Comprehensive Psychiatry, 2017, 76, 45-55.	3.1	10
42	Psychometric Properties and Normative Data of the Zuckerman–Kuhlman Personality Questionnaire in a Psychiatric Outpatient Sample. Journal of Personality Assessment, 2017, 99, 219-224.	2.1	7
43	[P3–233]: CORRELATIONS BETWEEN PLASMA AND BRAIN BETAâ€AMYLOID LEVELS IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE FUNDACIÓ ACE HEALTHY BRAIN INITIATIVE (FACEHBI). Alzheimer's and Dementia, 2017, 13, P1027.	0.8	0
44	[P1–554]: OPTIMAL HARMONIZATION OF COGNITIVE MEASURES ENHANCES THE DETECTION OF GENETIC EFFECTS ON ALZHEIMER'S DISEASE PROGRESSION: A COMPARISON OF SIX STATISTICAL APPROACHES IN 1796 MCI PATIENTS FROM THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P506.	0.8	0
45	Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype. Journal of Alzheimer's Disease, 2017, 57, 447-459.	2.6	26
46	Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic. Journal of Alzheimer's Disease, 2017, 58, 1099-1108.	2.6	9
47	FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-9.	2.7	22
48	Diagnostic Concordance Between Categorical and Dimensional Instruments to Assess Personality Disorder in Chronic Fatigue Syndrome. European Journal of Psychological Assessment, 2017, 33, 158-165.	3.0	1
49	Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 559-566.	2.6	9
50	Gender Differences in Demographic and Clinical Features of Physicians Admitted to a Program for Medical Professionals with Mental Disorders. Frontiers in Psychiatry, 2016, 7, 181.	2.6	9
51	Borderline Personality Disorder and Personality Inventory for DSM-5 (PID-5): Dimensional personality assessment with DSM-5. Comprehensive Psychiatry, 2016, 70, 105-111.	3.1	14
52	P2â€087: Genetic Determinants of Alzheimer's Disease Progression: Exploratory Analysis of International Genomics of Alzheimer Project (IGAP) Genetic Markers in MMSE Rate of Decline and GDS. Alzheimer's and Dementia, 2016, 12, P642.	0.8	0
53	P1â€120: Exploring International Genomics of Alzheimer's Project (IGAP) Genetic Markers' Effect on Age at Onset of Dementia in Alzheimer's Disease Patients. Alzheimer's and Dementia, 2016, 12, P448.	0.8	0
54	Cortisol awakening response in adults with attention deficit hyperactivity disorder: Subtype differences and association with the emotional lability. European Neuropsychopharmacology, 2016, 26, 1140-1149.	0.7	9

#	Article	IF	CITATIONS
55	Impulsive clinical profile of Borderline Personality Disorder with comorbid Substance Use Disorder. Actas Espanolas De Psiquiatria, 2016, 44, 145-52.	0.1	6
56	Study of prevalence of Personality Disorders in inmate men sample with Substance Use Disorders using of PDQ-4+ Self-Report. Actas Espanolas De Psiquiatria, 2016, 44, 178-82.	0.1	3
57	P3-196: Cognitive composites and prodromal Alzheimer's disease. , 2015, 11, P707-P708.		0
58	Concordance between Subjective and Objective Memory Impairment in Volunteer Subjects. Journal of Alzheimer's Disease, 2015, 48, 1109-1117.	2.6	30
59	Influence of Sampling and Recruitment Methods in Studies of Subjective CognitiveÂDecline. Journal of Alzheimer's Disease, 2015, 48, S99-S107.	2.6	40
60	To what extent is personality associated with time perspective?. Anales De Psicologia, 2015, 31, 488.	0.7	8
61	Reply to the Letter to the Editor: †Depression symptoms in burn patients†M. Burns, 2015, 41, 1895-1896.	1.9	0
62	Predicting treatment failure in pathological gambling: The role of personality traits. Addictive Behaviors, 2015, 43, 54-59.	3.0	41
63	Personality as a predictor of depression symptoms in burn patients: A follow-up study. Burns, 2015, 41, 25-32.	1.9	20
64	Validation of the Spanish Version of the Face Name Associative Memory Exam (S-FNAME) in Cognitively Normal Older Individuals. Archives of Clinical Neuropsychology, 2015, 30, 712-720.	0.5	22
65	Comorbid personality disorders in chronic fatigue syndrome patients: a marker of psychopathological severity. Actas Espanolas De Psiquiatria, 2015, 43, 58-65.	0.1	6
66	Motivational interviewing group at inpatient detoxification, its influence in maintaining abstinence and treatment retention after discharge. Revista De Psicologia De La Salud, 2015, 27, 109-18.	0.5	2
67	Neuroticism Associated with Cocaine-Induced Psychosis in Cocaine-Dependent Patients: A Cross-Sectional Observational Study. PLoS ONE, 2014, 9, e106111.	2.5	17
68	Rasgos de personalidad (ZKPQ) en pacientes con fibromialgia: un estudio de casos y controles Anales De Psicologia, 2014, 30, .	0.7	7
69	Doctors admitted to a Physicians' Health Program: a comparison of self-referrals versus directed referrals. BMJ Open, 2014, 4, e005248-e005248.	1.9	4
70	Association between cell-bound blood amyloid- $\hat{l}^2(1$ - 40) levels and hippocampus volume. Alzheimer's Research and Therapy, 2014, 6, 56.	6.2	9
71	Inpatient Physicians and Nurses With Dual Diagnosis: An Exploratory Study. Journal of Dual Diagnosis, 2014, 10, 156-161.	1.2	2
72	Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacology, 2014, 231, 1389-1395.	3.1	17

#	Article	lF	CITATIONS
73	Cognitive, Genetic, and Brain Perfusion Factors Associated with Four Year Incidence of Alzheimer's Disease from Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 41, 739-748.	2.6	30
74	Chronic fatigue syndrome and personality: A case-control study using the alternative five factor model. Psychiatry Research, 2014, 216, 373-378.	3.3	9
75	Early-age clinical and developmental features associated to Substance Use Disorders in Attention-Deficit/Hyperactivity Disorder in Adults. Comprehensive Psychiatry, 2014, 55, 639-649.	3.1	25
76	Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs. Alzheimer's and Dementia, 2014, 10, 409-415.	0.8	69
77	Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 719-727.	3.2	16
78	Promoting voluntary help-seeking among doctors with mental disorders. International Journal of Occupational Medicine and Environmental Health, 2014, 27, 435-43.	1.3	18
79	Dual Diagnosis Among Physicians: A Clinical Perspective. Journal of Dual Diagnosis, 2014, 10, 148-155.	1.2	19
80	Emotional lability: The discriminative value in the diagnosis of attention deficit/hyperactivity disorder in adults. Comprehensive Psychiatry, 2014, 55, 1712-1719.	3.1	30
81	Neuroticism and impulsivity: Their hierarchical organization in the personality characterization of drug-dependent patients from a decision tree learning perspective. Comprehensive Psychiatry, 2014, 55, 1227-1233.	3.1	32
82	Identification of Misdiagnosed Fronto-Temporal Dementia using APOE Genotype and Phenotype-Genotype Correlation Analyses. Current Alzheimer Research, 2014, 11, 182-191.	1.4	22
83	Attention deficit hyperactivity disorder in cocaineâ€dependent adults: A psychiatric comorbidity analysis. American Journal on Addictions, 2013, 22, 466-473.	1.4	42
84	Exploratory analysis of seven Alzheimer's disease genes: disease progression. Neurobiology of Aging, 2013, 34, 1310.e1-1310.e7.	3.1	15
85	Risk factors for cocaine-induced psychosis in cocaine-dependent patients. European Psychiatry, 2013, 28, 141-146.	0.2	36
86	The role of neuroticism, perfectionism and depression in chronic fatigue syndrome. A structural equation modeling approach. Comprehensive Psychiatry, 2013, 54, 1061-1067.	3.1	15
87	The role of personality in the prediction of treatment outcome in pathological gamblers: A follow-up study Psychological Assessment, 2013, 25, 599-605.	1.5	22
88	Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 2013, 16, 1267-1275.	2.1	56
89	Psychoeducation for Adults With Attention Deficit Hyperactivity Disorder vs. Cognitive Behavioral Group Therapy. Journal of Nervous and Mental Disease, 2013, 201, 894-900.	1.0	60
90	Effectiveness and Tolerability of Duloxetine in 2 Different Ethnic Samples. Journal of Clinical Psychopharmacology, 2013, 33, 254-256.	1.4	5

#	Article	IF	Citations
91	A Longitudinal Follow-Up of 550 Mild Cognitive Impairment Patients: Evidence for Large Conversion to Dementia Rates and Detection of Major Risk Factors Involved. Journal of Alzheimer's Disease, 2013, 34, 769-780.	2.6	164
92	Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual Adults Older than 44 Years Old. PLoS ONE, 2013, 8, e76436.	2.5	69
93	Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates. PLoS ONE, 2013, 8, e81334.	2.5	36
94	Feasibility of Double-Blind Clinical Trials with Oral Diacetylmorphine: A Randomized Controlled Phase II Study in an Inpatient Setting. European Addiction Research, 2012, 18, 279-287.	2.4	7
95	Effectiveness of combined individual and group dialectical behavior therapy compared to only individual dialectical behavior therapy: A preliminary study Psychotherapy, 2012, 49, 241-250.	1.2	22
96	Personality profile of adult ADHD: The alternative five factor model. Psychiatry Research, 2012, 198, 130-134.	3.3	18
97	Validez de criterio y concurrente de la versión española de la Conners Adult ADHD Diagnostic Interview for DSM-IV. Revista De PsiquiatrÃa Y Salud Mental, 2012, 5, 229-235.	1.8	45
98	Encuesta sobre la satisfacción de los pacientes dependientes de heroÃna de la Comunidad de Valencia con los centros de tratamiento con metadona. Trastornos Adictivos, 2012, 14, 66-72.	0.1	0
99	Normative data of a brief neuropsychological battery for Spanish individuals older than 49. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 209-219.	1.3	63
100	Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2012, 5, 229-235.	0.3	12
101	Effectiveness of a psycho-educational group program for major depression in primary care: a randomized controlled trial. BMC Psychiatry, 2012, 12, 230.	2.6	45
102	A Two-Year Follow-Up of Cognitive Deficits and Brain Perfusion in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 30, 109-120.	2.6	59
103	The SCID-II and DIB-R interviews: diagnostic association with poor outcome risk factors in Borderline Personality Disorder. Psicothema, 2012, 24, 523-8.	0.9	2
104	The alternative five-factor model of personality, nicotine dependence and relapse after treatment for smoking cessation. Addictive Behaviors, 2011, 36, 965-971.	3.0	25
105	Acculturative stress as a risk factor of depression and anxiety in the Latin American immigrant population. International Review of Psychiatry, 2011, 23, 84-92.	2.8	82
106	Brain Perfusion Correlates of Visuoperceptual Deficits in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 557-567.	2.6	30
107	Comorbid Attention-Deficit/Hyperactivity Disorder in Borderline Patients Defines an Impulsive Subtype of Borderline Personality Disorder. Journal of Personality Disorders, 2010, 24, 812-822.	1.4	84
108	Impacto de la sintomatologÃa depresiva en los resultados de un programa de deshabituación tabáquica en el lugar de trabajo. Revista De Psicologia De La Salud, 2010, 22, 101.	0.5	3

#	Article	IF	Citations
109	Ecological assessment of executive functions in mild cognitive impairment and mild Alzheimer's disease. Journal of the International Neuropsychological Society, 2009, 15, 751-757.	1.8	59
110	Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 860-867.	1.3	52
111	Association Study of 10 Genes Encoding Neurotrophic Factors and Their Receptors in Adult and Child Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2008, 63, 935-945.	1.3	93
112	Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate. CNS Drugs, 2008, 22, 603-611.	5.9	47
113	Discriminant Validity of the ZKPQ in a Sample Meeting BPD Diagnosis vs. Normal-Range Controls. Journal of Personality Disorders, 2008, 22, 178-190.	1.4	21
114	Dual diagnosis in inpatient physicians: prevalence and clinical characteristics. Mental Health and Substance Use: Dual Diagnosis, 2008, 1, 10-20.	0.5	10
115	ZUCKERMAN-KUHLMAN PERSONALITY QUESTIONNAIRE: PSYCHOMETRIC PROPERTIES IN A SAMPLE OF THE GENERAL POPULATION1. Psychological Reports, 2008, 103, 843-836.	1.7	1
116	ZUCKERMAN-KUHLMAN PERSONALITY QUESTIONNAIRE: PSYCHOMETRIC PROPERTIES IN A SAMPLE OF THE GENERAL POPULATION. Psychological Reports, 2008, 103, 845.	1.7	23
117	Working memory in siblings of schizophrenia patients. Schizophrenia Research, 2007, 95, 70-75.	2.0	51
118	Consensual Validity Parameters of the Zuckerman–Kuhlman Personality Questionnaire: Evidence From Self-Reports and Spouse Reports. Journal of Personality Assessment, 2005, 84, 279-286.	2.1	35
119	Patient perspectives on methadone maintenance treatment in the Valencia Region: Dose adjustment, participation in dosage regulation, and satisfaction with treatment. Drug and Alcohol Dependence, 2005, 79, 405-412.	3.2	31
120	A satisfaction survey of opioid-dependent clients at methadone treatment centres in Spain. Drug and Alcohol Dependence, 2004, 73, 307-313.	3.2	34
121	Psychometric Properties of the Zuckerman-Kuhlman Personality Questionnaire in a Spanish Sample. European Journal of Psychological Assessment, 2004, 20, 134-146.	3.0	41
122	Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT). Drug and Alcohol Dependence, 2002, 68, 209-214.	3.2	35